Clinical trial
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic…
NCT00102024 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00102024 |
|---|---|
| Title | Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma |
| Official title | A Phase I/II, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Single Dose 90Y-Labeled IDEC-159, Humanized, Domain Deleted, Anti TAG-72 Monoclonal Antibody, in Subjects With Metastatic Colorectal Adenocarcinoma |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Metastases |
| Intervention type | Drug |
| Interventions | Unconjugated IDEC-159, 111In-IDEC-159, 90Y-IDEC-159 |
| Enrollment | 30 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Jan 20, 2005 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: